Global Ornithine Aspartate for Injection Market Insights and Forecast to 2028

Market Analysis and Insights: Global Ornithine Aspartate for Injection Market
Due to the COVID-19 pandemic, the global Ornithine Aspartate for Injection market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 0.05 accounting for % of the Ornithine Aspartate for Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hepatic Encephalopathy segment is altered to an % CAGR throughout this forecast period.
China Ornithine Aspartate for Injection market size is valued at US$ million in 2021, while the US and Europe Ornithine Aspartate for Injection are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Ornithine Aspartate for Injection landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Ornithine Aspartate for Injection include Dexa Medica, TCI America, Kyowa Hakko, Qi Rui Yao Ye and MERS, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Ornithine Aspartate for Injection Scope and Segment
Ornithine Aspartate for Injection market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Ornithine Aspartate for Injection market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type
0.05
0.1

Segment by Application
Hepatic Encephalopathy
Hepatitis
Liver Cirrhosis
Fatty Liver
Post-hepatitis Syndrome
Other

By Company
Dexa Medica
TCI America
Kyowa Hakko
Qi Rui Yao Ye
MERS

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE